Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.
Paclitaxel and pegylated liposomal doxorubicin hydrochloride (PLDH), each on its own or with platinum, were recommended because they work better and cost less than other treatments available on the NHS.
Gemcitabine with carboplatin and trabectedin with PLDH were not recommended because although they work about as well as other treatments available on the NHS they cost more.
Topotecan was not recommended because it does not work as well as other treatments available on the NHS and costs more.